Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

Raltegravir is the preferred INSTI for for treatment of antiretroviral-naïve pregnant women in the US Perinatal Guidelines, alongside Dolutegravir, and for late pregnancy. There are relatively limited information available on its use during early pregnancy, particularly the peri-conception period. The aim of the study is to assess "real-world" maternal, fetal and newborn outcomes following RAL use during pregnancy through pooled analysis of individual patient data from observational studies participating in the European Pregnancy and Paediatric Infections Cohort Collaboration.

Start Date20 Feb 2023

Sponsor / Collaborator

Fondazione Penta Onlus

NCT03954327 / CompletedPhase 2IIT

Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

Start Date01 Mar 2021

Sponsor / Collaborator

University of Alberta

[+1]

EUCTR2019-004195-19-IT / Unknown statusPhase 2

A randomized comparative phase II trial evaluating the capacity of the dualcombination doravirine/raltegravir to maintain virological success in HIV-1infected patients with an HIV-RNA plasma viremia below 50 copies/mL under acurrent antiretroviral regimen. - DORAL

Start Date12 Nov 2020

Sponsor / Collaborator-

100 Clinical Results associated with Raltegravir Potassium

100 Translational Medicine associated with Raltegravir Potassium

100 Patents (Medical) associated with Raltegravir Potassium

2,274

Literatures (Medical) associated with Raltegravir Potassium

01 Mar 2024·Journal of pharmaceutical and biomedical analysis

Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring

Article

Author: Devanathan, Aaron S ; Riddler, Sharon A ; Nolin, Thomas D ; Oberly, Patrick J ; West, Raymond E

Antiretroviral therapy (ART) is highly effective for the treatment of HIV-1 infection. ART previously consisted of concomitant administration of many drugs, multiple times per day. Currently, ART generally consists of two- or three-drug regimens once daily as fixed-dose combinations. Drug monitoring may be necessary to ensure adequate concentrations are achieved in the plasma over the dosing interval and prevent further HIV resistance formation. Additionally, nonadherence remains an issue, highlighting the need to ensure sufficient ART exposure. Towards this effort, we developed and validated a highly selective ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous quantification of a panel of nine antiretrovirals: abacavir, bictegravir, cabotegravir, dolutegravir, doravirine, emtricitabine, lamivudine, raltegravir, and tenofovir in human plasma. Using only 50 µL of plasma, a simple protein precipitation with acetonitrile with internal standards followed by reconstitution in 50 uL (high) or 400 uL (low) was performed. Analyte separation was achieved using a multistep UPLC gradient mixture of (A: 0.1% formic acid in water and B: acetonitrile) and a Waters CORTECS T3 (2.1 ×100 mm) column. The method was comprehensively validated according to the United States Food and Drug Administration Bioanalytical Guidelines over two clinically relevant ranges (1-250 ng/mL and 100-5000 ng/mL) with excellent linearity (R² > 0.99 for all). The assay run time was 7.5 min. This method achieves acceptable performance of trueness (89.7-104.1%), repeatability, and precision (CV <15%), and allows for simultaneous quantification of guideline-recommended ART regimens. This method can be utilized for the therapeutic monitoring of antiretrovirals in human plasma.

01 Feb 2024·Archivos argentinos de pediatria

Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay.

Article

Author: Gutiérrez Rodríguez, Stella I ; Sande, Verónica ; González Castro, Ana V ; Pardo Casaretto, Lorena V

Antiretroviral (ARV) drug resistance is a public health issue. Resistance has also been observed in the case of integrase strand transfer inhibitors (INSTIs) used in pediatrics. The objective of this article is to describe 3 cases of INSTI resistance. These are the cases of 3 children with vertically-transmitted human immunodeficiency virus (HIV). They were started on ARVs as infants and preschoolers, with poor treatment adherence, and had different management plans due to associated comorbidities and virological failure due to resistance. In the 3 cases, resistance developed rapidly as a result of virological failure and INSTI involvement. Treatment adherence should be monitored so that any increase in viremia can be detected early. Virological failure in a patient treated with raltegravir forces to a rapid change in ARV therapy because its continued use may favor new mutations and resistance to second-generation INSTIs.

01 Feb 2024·Pharmacogenetics and genomics

Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens

Article

Author: Koethe, John ; Samuels, David C ; Brown, Todd ; Wu, Kunling ; Bares, Sara H ; Haas, David W ; Tassiopoulos, Katherine ; Lake, Jordan E ; Hulgan, Todd ; Leonard, Michael ; Erlandson, Kristine

Background:

Excessive weight gain affects some persons with HIV after switching to integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART). We studied associations between CYP2B6 genotype and weight gain after ART switch among ACTG A5001 and A5322 participants.

Methods:

Eligible participants switched from efavirenz- to INSTI-containing ART, had genotype data, and had weight data at least once from 4 weeks to 2 years post-switch. Multivariable linear mixed effects models adjusted for race/ethnicity, CD4, age, BMI and INSTI type assessed relationships between CYP2B6 genotype and estimated differences in weight change.

Results:

A total of 159 eligible participants switched ART from 2007 to 2019, of whom 138 had plasma HIV-1 RNA < 200 copies/mL (65 CYP2B6 normal, 56 intermediate, 17 poor metabolizers). Among participants with switch HIV-1 RNA < 200 copies/mL, weight increased in all 3 CYP2B6 groups. The rate of weight gain was greater in CYP2B6 poor than in CYP2B6 normal metabolizers overall, and within 9 subgroups (male, female, White, Black, Hispanic, dolutegravir, elvitegravir, raltegravir, and TDF in the pre-switch regimen); only in Hispanic and elvitegravir subgroups were these associations statistically significant (P < 0.05). Compared to normal metabolizers, CYP2B6 intermediate status was not consistently associated with weight gain.

Conclusion:

CYP2B6 poor metabolizer genotype was associated with greater weight gain after switch from efavirenz- to INSTI-containing ART, but results were inconsistent. Weight gain in this setting is likely complex and multifactorial.

News (Medical) associated with Raltegravir Potassium

21 Jun 2024

·www.biospace.com

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL event to discuss APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor, on Monday, June 24, 2024 at 9:00 AM ET. To register, click here. The webinar will feature Joseph Vacca, PhD, Medicinal Chemistry Expert and Consultant to Aprea, who will discuss the medicinal chemistry history, highly selective drug design, and preclinical findings of APR-1051. It will also feature Eric J. Brown, PhD (University of Pennsylvania) who will discuss preclinical findings across the WEE1 inhibitor class. WEE1 is an enzyme involved in the DNA damage response pathway and is a validated oncology target. APR-1051 is a potent and selective small molecule that has been designed to limit off-target toxicity. Aprea recently initiated the Phase 1 ACESOT-1051 trial evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need, including patients with Cyclin E over expression. A live question and answer session will follow the formal presentations. Joseph Vacca, PhD is a medicinal chemist who spent 30 years at Merck Research Laboratories (1981 to 2011). He and his teams made major contributions to several approved drugs including the HIV protease inhibitor CRIXIVAN™ (indinavir sulfate), the HIV integrase inhibitor Isentress™ (raltegravir); the HCV protease Inhibitor (Vanihep™, vaniprevir), the combination product Zepatier™ which is a combination of the second generation HCV protease Inhibitor grazoprevir and the NS5A protein Inhibitor elbasvir and the recently approved second generation HIV NNRTI inhibitor doravirine. Upon his retirement from Merck in 2011, Dr. Vacca took a role as Senior Vice President of Early Success Sharing Partnerships at WuXi AppTec Limited. He left WuXi in September 2015 to be a consultant and now acts as an interim head of chemistry for several small startup companies. Dr. Vacca has over 100 publications and patents and is the holder of many awards including a Merck Directors Award (1998); PhRMA Discoverers Award (1999); Intellectual Property Owners “National Inventor of the year Award” (1997); European Inventor of the Year (non-EU nation) (2007); ACS “Award for Creative Invention” (1999); and was a named a Merck Research Laboratories Presidential Fellow in 2008. He was named to the American Chemical Society Medicinal Chemistry Hall of Fame (Aug. 2012) and was also named a “Hero of Chemistry” (along with the research team) for his role in the discovery and development of the HIV integrase inhibitorIsentress™. Dr. Vacca earned a BS in chemistry in 1977 from St. John Fisher College, Rochester, New York, and obtained a PhD degree in Organic Chemistry under Professor Peter T. Lansbury Sr. at the State University of New York at Buffalo (New York). Eric J. Brown, PhD is Associate Professor of Cancer Biology at the University of Pennsylvania and a Scientific Consultant to Aprea Therapeutics. Dr. Brown’s laboratory at Penn focuses on the role of the replication stress response on genome stability. His research seeks to identify the cancer-associated genetic changes that increase the efficacy of therapeutics that abrogate replication stress responses, such as ATR and WEE1 inhibitors. The genetic changes that impact sensitivity to these therapies are identified through various orthogonal approaches, including proteomics, genome-wide breakpoint mapping, and computational methods. Overall, the goal of this research is both to better understand the mechanism by which these cancer therapeutics operate and to improve responses to these treatments in patients. About Aprea Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at . The Company may use, and intends to use, its investor relations website at as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Forward-Looking Statement Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law. Investor Contact: Mike Moyer LifeSci Advisors mmoyer@lifesciadvisors.com

Phase 1Executive Change

23 Aug 2023

·www.biospace.com

The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023

Pictured: Series of outcroppings with steep cliffs down to the ocean/iStock, honster The biopharma industry has been creeping over a patent cliff for months, with several drugs losing their primary patents and more patents expected to expire in the next seven years. This opens the door for new generics to enter the market, lowering drug prices and therefore reducing how much manufacturers can rake in from brand name products. Maria Whitman, global head of ZS Associates’ pharmaceutical and biotech practice, previously told BioSpace that drugs going off-patent could impact between up to 79% of a company’s revenues. Drug prices go down any time a new generic becomes available, but the impact may be more pronounced around patent cliffs. One analysis found that the steepest price declines for brand name drugs between 2008 and 2014 occurred when the first three generics were introduced. Not every company will experience this decline in the same way. For example, Eraxis, an antifungal drug owned by Pfizer, is expected to lose its exclusivity in September. But loss of exclusivity probably won’t have a major impact on the company, said S. Sean Tu, a law professor at West Virginia University and affiliated faculty at Harvard Medical School’s Program on Regulation, Therapeutics and Law. “Even if a lot of generics [for Eraxis] went on the market tomorrow, I don’t think it would hurt Pfizer’s bottom line. They have a pretty diverse portfolio,” Tu told BioSpace. Smaller companies like Eiger Pharmaceuticals may have more to lose. The company has one commercial product, Zokinvy, that will start losing exclusivity soon. In SEC filings, Eiger warns investors that it may never be profitable. Just because the primary patent for a drug expires, it doesn’t automatically mean other companies are free to start marketing generics. For example, AbbVie filed hundreds of patents for its biologic drug Humira, preventing other companies from producing generic adalimumab. It was only after a 2017 settlement that Amgen was able to start marketing biosimilars overseas, and eventually in the U.S. in January of this year. Then, last month, a flood of new Humira biosimilars hit the market. Owning multiple patents for a single drug, what’s known as patent thickets, help drug companies make up for lost time and costs during the FDA approval process, according to Tu. However, more companies are relying on them to limit competition. A research letter authored by Tu and others found that recently approved drugs have more patents filed and more patents litigated compared to older drugs, leading to delays in generics entering the market. Here are some drugs that may see generic versions enter the market soon. Takeda’s Vyvanse, Aug. 24 Vyvanse (lisdexamfetamine dimesylate) is an oral amphetamine used for attention-deficit hyperactive disorder. New River Pharmaceuticals filed a provisional application for the drug in 2003 and the patent was issued in 2007. It was eventually acquired by Shire and later Takeda, bringing in $2.52 billion for the Japanese company between March 2021 and 2022. The patents covering adult indications of Vyvanse expired on Feb. 24, and those for the pediatric indications are due to expire Aug. 24. As of July 31, there were 12 tentative approvals for Vyvanse generics, with some issued as early as 2014 and others as recently as June 14, 2023. Companies looking to market these generics include Teva, Mylan and Sandoz. Tu predicted that the breadth of Takeda’s portfolio would minimize the impact of the loss. Indeed, a financial forecast filed by the company July 27 says that growth and launch of new products are “largely offsetting” the impact of losing Vyvanse’s exclusivity. Pfizer’s Eraxis, Sept. 22 Eraxis (anidulafungin) is an intravenous antifungal drug. Its patent expired in 2020, but it’s under an exclusivity clause for the treatment of a new patient population that expires Sept. 22. Tu noted that he didn’t see any generic approvals in the pipeline for anidulafungin and therefore doesn’t anticipate a major loss of sales. The lack of generics runs contrary to predictions that generic anidulafungin would enter the market between early 2020 and mid-2022. Johnson & Johnson’s Stelara, Sept. 25 Stelara (ustekinumab) is a biologic used for psoriasis and Crohn’s disease. A patent for one of the molecules involved in Stelara expires Sept. 25. The drug already has some competition: J&J settled with Alvotech and Teva earlier this year preventing them from marketing biosimilars until 2025. Stelara is not the only drug driving pharmaceuticals sales growth, according to SEC filings, but it brought in more than 10% of the company’s revenue in 2022. Analysts predict that Stelara sales will fall $2 billion in 2024. Merck’s Isentress, Oct. 3 Isentress (raltegravir) is an antiretroviral drug used to treat HIV. It brought in $633 million in 2022, but sales have been declining due to competition, according to SEC filings. Some of the drug’s patents expired earlier this year, and two more are expected to expire soon, starting in October. Hetero Labs has received a tentative approval for generic raltegravir. Eiger’s Zokinvy, Oct. 17 Zokinvy (lonafarnib) is the first drug for rapid aging disorder progeria and Eiger Pharmaceuticals’ first commercial product. The drug, acquired from Merck, brought in $12 million for the company in 2022 and $4.1 million in the first quarter of 2023. The drug’s patents are expected to expire Oct. 17, 2023, and July 26, 2024, respectively. However, it has exclusivity clauses extending into 2027, which will protect the drug for a while. Additionally, there do not appear to be any immediate competitors. Astellas’ Myrbetriq, Nov. 4 Myrbetriq (mirabegron) is a urinary incontinence drug that garnered $1.35 billion for Astellas in 2022. More than one patent is expiring Nov. 4, and additional patents are expected to expire in May 2024. A recent court decision invalidated a patent that was set to expire in 2030, which the company plans to appeal. Zydus Cadila and Lupin Labs are among the companies that have tentative approvals for mirabegron generics. Novartis’ Entresto, Nov. 27 Entresto is a heart failure medication that combines sacubitril and valsartan. Some patents expired earlier this year, and more are slated to expire in November and the first half of 2024. Additionally, a patent set to expire in 2025 was recently invalidated by a court. Mylan is one company looking to offer generic Entresto. Novartis has settled with other companies looking to market the drug, according to SEC filings. Amgen’s Otezla, Dec. 9 Otezla (apremilast) is a psoriasis drug. Multiple patents for this drug expired in March of this year, and a patent for a specific formulation of the drug is expected to expire in December. Some of its exclusivity clauses also expired earlier this year. There are already multiple tentative approvals for generics in the wings, but recent court rulings have blocked drugmakers from marketing generic apremilast until 2028. Novo Nordisk’s Victoza and Saxenda, Dec. 30 Novo Nordisk’s liraglutide recombinant injections have patents expiring at the end of this year and in the first half of 2024. This includes the primary patent for diabetes drug Victoza, which brought in $1.8 billion in 2022. Teva, Pfizer and Mylan are expected to launch their generic liraglutide products in June 2024, per SEC filings. Sandoz is also cleared to launch its version of Victoza in 2024. Saxenda brought in $1.5 billion in 2022, and the weight loss drug’s main patent expired in February of this year. Novo sued Orbicular Pharmaceutical Technologies and Sun Pharma in 2022 for attempting to market generic versions of the drug. Novo still maintains a stronghold in the diabetes drug industry with Ozempic, which has also lost patents but likely won’t see generics until 2031. Ozempic sales will likely offset any losses from Victoza and Saxenda; the former brought in $2.9 billion in the first quarter of 2023, compared to $415 million for Victoza and $483 million for Saxenda. Nadia Bey is a freelance reporter in North Carolina. She can be reached at beynadiaa@gmail.com.

AcquisitionDrug ApprovalPatent ExpirationBiosimilar

24 Mar 2023

·www.sciencedaily.com

A readily available dietary supplement may reverse organ damage caused by HIV and antiretroviral therapy

MitoQ, a mitochondrial antioxidant that is available to the public as a diet supplement, was found in a mouse study to reverse the detrimental effects that HIV and antiretroviral therapy (ART) have on mitochondria in the brain, heart, aorta, lungs, kidney and liver. MitoQ, a mitochondrial antioxidant that is available to the public as a diet supplement, was found in a mouse study to reverse the detrimental effects that HIV and antiretroviral therapy (ART) have on mitochondria in the brain, heart, aorta, lungs, kidney and liver. The researchers used a molecular method to measure the ratio of human and murine mitochondrial (mtDNA) to nuclear DNA (ntDNA) ratio, a measure of mitochondrial dysfunction. Reduction in this ratio reflects mitochondrial dysfunction. Compared to uninfected mice, HIV infected mice treated with ART had mitochondrial dysfunction in the human immune cells in the brain, heart, liver, lungs, and gut. ART itself also affected mitochondrial function in mouse heart cells. When treated with MitoQ for 90 days, HIV infected mice had reduced mitochondrial dysfunction in organs compared to HIV infected mice on ART. Mitochondria are the key cell structures that are important for the smooth function of organs such as the brain, heart, liver and kidney. HIV causes a chronic state of inflammation and immune dysfunction that contribute to organ damage organs. The reasons for this are unclear, but it is known that mitochondrial dysfunction contributes to organ damage and is present in chronic HIV. There are no therapies for HIV associated diseases that affect organs such as the brain, heart and liver. The researchers used humanized mice, which have human immune cells that can be infected with HIV. They infected them with the virus, treated them with ART consisting of tenofovir disoproxil fumarate, emtricitabine, and raltegravir, then fed them MitoQ through drinking water for three months. The control mice were not given MitoQ. The researchers note that humanized mice do not exactly recreate HIV infection in humans. Also, the infected mice were exposed to both the virus and the ART and they could not dissect the exact contribution of the virus versus the ART to mitochondrial dysfunction in human cells. These preclinical findings could serve as the foundation for clinical trials in humans with HIV. "MitoQ is a diet supplement that is known to be safe in humans and is readily available for use," said senior author Dr. Theodoros Kelesidis, associate professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA. "Our findings support clinical trials of MitoQ in people with HIV who take antiretrovirals to determine whether it can be a potential treatment for comorbidities associated with chronic HIV infection. Until then people with HIV should not take this diet supplement for treatment of any conditions associated with HIV infection." The study was funded by the National Institutes of Health (R01AG059501, R21AI36708, R21HL134444, R03AG059462, R03AG059462, K08AI108272), the California HIV/AIDS Research Program (OS17-LA-002), and Campbell Foundation.

Clinical Study

100 Deals associated with Raltegravir Potassium

External Link

KEGG	Wiki	ATC	Drug Bank
D07133	Raltegravir Potassium	J05AX08	DB06817

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	US	Merck Sharp & Dohme Corp.	12 Oct 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	NDA/BLA	EU	Viatris Ltd. (New Zealand)	-
Kidney Failure, Chronic	Phase 3	FR	Merck Sharp & Dohme Corp.	01 Dec 2011
Hypertriglyceridemia	Phase 3	US	Merck Sharp & Dohme Corp.	01 May 2009
Primary Biliary Cholangitis	Phase 2	CA	Merck Sharp & Dohme Corp.	01 Mar 2021
Renal Insufficiency	Phase 2	-	Merck Sharp & Dohme Corp.	03 Sep 2014
Hyperlipidemias	Phase 2	AT	Merck Sharp & Dohme Corp.	01 May 2014
Multiple sclerosis relapse	Phase 2	GB	Merck Sharp & Dohme Corp.	01 Apr 2013
Multiple Sclerosis, Relapsing-Remitting	Phase 2	GB	Merck Sharp & Dohme Corp.	01 Apr 2013
HTLV-I Infections	Phase 2	-	Merck Sharp & Dohme Corp.	01 Jan 2012
End Stage Liver Disease	Phase 2	FR	Merck Sharp & Dohme Corp.	01 May 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01641367 (ACTG A5288, Pubmed)	Phase 4	Third line	257	RAL	jdsmsfbbak(plxrcrsbaz) = dhojdgkoln lybtsescvi (gulmudkajn ) View more	-	01 Jun 2022
				DRV/r	wwzpfyqrjq(wxdxwstvio) = rxchtnazfn sisazizkik (vgfnlhyuyu )
IAS2022	Not Applicable	HIV Infections	-	RAL granules	eymuepqgyd(hjbqcwmela) = nfaiyorbut jjjrjhtzmc (qsmdxkakzo )	-	01 Jan 2022
				Non-RAL regimens	eymuepqgyd(hjbqcwmela) = fneimghvhm jjjrjhtzmc (qsmdxkakzo )
NCT03374358 (Pubmed \| AIDS Patient Care STDS)	Phase 4	-	43	Switch to Raltegravir	enbkxuqcul(mffsjjdocq) = fvgkspzgnz qbmjcdaggg (jqnmnlfwci ) View more	-	01 Sep 2021
				Continue unchanged antiretroviral therapy	kjktgteheo(cjnjcbehhj) = tfliicujhy sbcjtnhykh (mduxgemnen )
NCT01147107 (CTgov)	Phase 4	HIV Infections \| Hepatitis C, Chronic	80	Raltegravir (Raltegravir Based Therapy)	ybbjrbujha(jmciawpgob) = iepemzgduw joikxcibfm (xrwfwugkzs, bkqaqqhvcw - qvgwhcukpf) View more	-	13 Aug 2021
				Efavirenz (Efavirenz Based Therapy)	ybbjrbujha(jmciawpgob) = lyhwvptmik joikxcibfm (xrwfwugkzs, zklubsjems - oozojttpzk) View more
NCT03374358 (CTgov)	Phase 4	Metabolic Syndrome \| Fatty Liver \| HIV Seropositivity	45	raltegravir	qzlmecoryw(ltlzfkhiec) = xiqwioaqbr gprotgdjcl (vdijycboql, mahpruiurh - qejsrijvqv) View more	-	07 Jul 2021
NCT03205566 (CTgov)	Phase 4	HIV Infections	38	Raltegravir (Raltegravir)	dhedcihlly(abbfwrrokz) = tsalxqetll xohzbbykpb (oxlyfbzuxk, eygzxfiefm - fmyyomplno) View more	-	21 Feb 2021
				Raltegravir (Raltegravir During Combination Treatment)	dhedcihlly(abbfwrrokz) = gfbysktvgn xohzbbykpb (oxlyfbzuxk, khxgeqikux - fgxibpowvd) View more
NCT01751568 (CTgov)	Phase 1/2	Tuberculosis \| HIV Infections	40	Raltegravir (Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment)	aqlakkccxh(cenbnvgzai) = cuqrpttapi anzxuvpcyc (tpsbwxorps, yacvczghkn - tqsxrchqlm) View more	-	21 Dec 2020
				Raltegravir (Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment)	aqlakkccxh(cenbnvgzai) = meayhalhzp anzxuvpcyc (tpsbwxorps, anapwnefww - gkmgamxknd) View more
NCT00752856 (CTgov)	Phase 2	HIV Infections	51	Kaletra+Isentress (1 - Kaletra + Isentress Taken Twice Daily)	rchwcdttvi(ysxqyjhnor) = cykjbpgckt hefrgwqezv (ovrpztxeuj, hygdyqqgef - ungeqfcqte) View more	-	07 Jul 2020
				Atripla (2 - Atripla Taken Once Daily)	rchwcdttvi(ysxqyjhnor) = xomivqjfea hefrgwqezv (ovrpztxeuj, yqvqffovhc - zqcnhfvqrc) View more
NCT02577042 (CTgov)	Phase 4	Inflammation \| HIV Infections	42	atorvastatin+raltegravir (Raltegravir + Atorvastatin)	goexjyjygy(tuulkspeot) = rqbnvaspcv ailabxwyex (bqilzdxwur, wiaffuqfpb - uarbhdrmhr) View more	-	22 Jun 2020
				Kivexa+atorvastatin+Truvada (PI-based Regimen + Atorvastatin)	goexjyjygy(tuulkspeot) = qfxavodwzl ailabxwyex (bqilzdxwur, rxhdgeesfa - etrqlvjpbk) View more
ANRS 12300 (IAS2020)	Not Applicable	Tuberculosis \| HIV Infections	460	Raltegravir 400mg BID	bdtmtyikeb(eopozdtujk) = lbgvjrunlj rxthrivlqp (daokgsejzd )	Negative	01 Jan 2020
				Efavirenz 600mg QD	bdtmtyikeb(eopozdtujk) = jtzfbqtpzu rxthrivlqp (daokgsejzd )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis